Hans Biomed한스바이오메드

Hans Biomed's revenue is growing, but losses widened sharply in 2025 and the first half of 2026 remains loss-making.

Hans Biomed makes skin and bone graft products and medical devices, selling through hospitals and distributors in Korea and overseas. Trailing twelve-month revenue is about ₩110.5B, but operating loss is about ₩20.4B and net loss about ₩24.8B, with liabilities equal to 100% of equity. The share price is ₩18,580, down 31.7% over one year but up 4.9% over one month, with a market value of about ₩265B.

What stands out

• Revenue rose 10.7% in 2025 to about ₩89.8B, but the operating margin fell to -28.8% and the net loss widened to about ₩31.3B.
• Trailing results to H1 2026 show an operating margin of -18.5%, an improvement on 2025 but still loss-making, and free cash flow of about -₩22.7B.
• Cash of about ₩18.0B is well below borrowings of about ₩40.3B, based on the filed figures.
• Price-to-book is 3.6 and price-to-sales is 2.4; P/E is not meaningful because earnings are negative, and the dividend yield is 0%.
• Foreign ownership rose from 5.2% to 6% over about 60 days, while retail investors were net sellers of about ₩2.6B over the last 20 days.

What to watch

• Full-year 2026 results and the next half-year or quarterly filings, to see whether losses narrow and cash burn eases against the ₩40.3B borrowings.
• Further 5%+ holding reports, which have been frequent since June 2026; the data does not say what they signal.
• The data includes no news headlines and no analyst forecasts, so the company's outlook beyond the filings is not known from this information.